Teva launches generic insomnia treatment in US

Brand Lunesta had $852 million in US sales in 2013.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic Lunesta, for the treatment of insomnia, in the US.

Brand Lunesta, marketed by Sunovion Pharmaceuticals Inc., had $852 million in US sales in 2013, according to IMS.

Glenmark Generics Ltd. and Mylan Inc. (Nasdaq: MYL) also obtained marketing approval for generic Lunesta.

Published by Globes [online], Israel business news - - on April 16, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018